MedElevator
Войти в исследования Frontiers in cellular and infection microbiology · 2026
CLEC3A-derived peptides exhibit broad-spectrum activity against Candida auris and clinically relevant pathogens.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mies Katinka, Hermes Gabriele, Beckers Jens, Mörgelin Matthias, Simon Michaela, Rügamer Tamara, Jantsch Jonathan, Klatt Andreas R, Streichert Thomas, Elezagic Dzemal
Аннотация
INTRODUCTION: Antimicrobial resistance in bacterial and fungal pathogens poses a major threat to global health, with Candida auris recently classified by the WHO as a critical priority pathogen. Antimicrobial peptides (AMPs) have emerged as promising candidates due to their broad-spectrum activity and membrane-disruptive mechanisms.
METHODS: In this study, the antibacterial and antifungal efficacy of two CLEC3A-derived peptides, HT-47 and WRK-30, was evaluated in comparison to the reference AMP LL-37 and the drugs amphotericin B and penicillin/streptomycin using viable count assays, biofilm assays, and scanning and transmission electron microscopy.
RESULTS: HT-47 and WRK-30 showed antibacterial activity against the ESKAPE pathogens K. pneumoniae and A. baumannii, as well as antifungal effects against C. albicans, C. neoformans, and particularly C. auris, with MIC50 values comparable to or lower than amphotericin B. Both peptides significantly inhibited more potent C. auris biofilm formation, compared to amphotericin B. SEM and TEM revealed extensive membrane and subcellular damage in peptide-treated fungal cells.
CONCLUSION: CLEC3A-derived peptides HT-47 and WRK-30 exhibit potent and comparable antibacterial and antifungal activity, highlighting their potential as therapeutic candidates for combating multidrug-resistant pathogens, including C. auris.
METHODS: In this study, the antibacterial and antifungal efficacy of two CLEC3A-derived peptides, HT-47 and WRK-30, was evaluated in comparison to the reference AMP LL-37 and the drugs amphotericin B and penicillin/streptomycin using viable count assays, biofilm assays, and scanning and transmission electron microscopy.
RESULTS: HT-47 and WRK-30 showed antibacterial activity against the ESKAPE pathogens K. pneumoniae and A. baumannii, as well as antifungal effects against C. albicans, C. neoformans, and particularly C. auris, with MIC50 values comparable to or lower than amphotericin B. Both peptides significantly inhibited more potent C. auris biofilm formation, compared to amphotericin B. SEM and TEM revealed extensive membrane and subcellular damage in peptide-treated fungal cells.
CONCLUSION: CLEC3A-derived peptides HT-47 and WRK-30 exhibit potent and comparable antibacterial and antifungal activity, highlighting their potential as therapeutic candidates for combating multidrug-resistant pathogens, including C. auris.